Aethlon Medical在澳大利亚接受第二次血净化者癌症试验的道德认证。 Aethlon Medical receives a second ethics approval for a Hemopurifier® cancer trial in Australia.
Aethlon Medicals获得澳大利亚Bellberry人类研究伦理委员会(BHREC)第二次批准。 Aethlon Medical receives its second ethics approval for a Hemopurifier® cancer trial from Australia's Bellberry Human Research Ethics Committee (BHREC). 试验将调查在接受抗PD-1单疗法治疗的固态肿瘤患者体内的血净化器,重点是安全性、可行性和最佳剂量。 The trial will investigate the Hemopurifier® in patients with solid tumors receiving anti-PD-1 monotherapy treatments, with a focus on safety, feasibility, and optimal dosing. 这是在该公司6月份获得皇家阿德莱德医院道德委员会批准的基础上进行的。 This builds upon the company's previous approval from the Royal Adelaide Hospital's ethics committee in June. 试验的目的是通过捆绑和从血液中除去肿瘤产生的外细胞囊,提高抗PD-1抗体的治疗反应率。 The trial aims to improve therapeutic response rates to anti-PD-1 antibodies by binding and removing tumor-produced extracellular vesicles from the bloodstream. 这项研究由马科·马托斯博士领导,计划招收大约9-18名病人。 The study, led by Dr. Marco Matos, plans to enroll approximately 9-18 patients.